https://www.gsk.com/en-gb/media/press-releases/dreamm-7-phase-iii-trial-shows-pfs-improvement-and-strong-os-trend-for-blenrep-combo-versus-soc-combo-in-multiple-myeloma/
Results from an interim analysis of the DREAMM-7 phase III head-to-head trial.
phase iii trialshowsblenrepcombinationnearly